 AIM ImmunoTech Inc NYSE:AIM has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen rintatolimod with checkpoint blockade therapies. In a statement, AIM ImmunoTech CEO Thomas Equels said: We have amassed a growing body of encouraging Ampligen data to date through close collaborations with leading KOLs at preeminent institutions. 